Literature DB >> 15528231

Effects of chronic administration of clenbuterol on function and metabolism of adult rat cardiac muscle.

Gopal K R Soppa1, Ryszard T Smolenski, Najma Latif, Ada H Y Yuen, Aalya Malik, Joanna Karbowska, Zdzislaw Kochan, Cesare M N Terracciano, Magdi H Yacoub.   

Abstract

Clenbuterol (Clen), a beta(2)-agonist, is known to produce skeletal and myocardial hypertrophy. This compound has recently been used in combination with left ventricular assist devices for the treatment of end-stage heart failure to reverse or prevent the adverse effects of unloading-induced myocardial atrophy. However, the mechanisms of action of Clen on myocardial cells have not been fully elucidated. In an attempt to clarify this issue, we examined the effects of chronic administration of Clen on Ca(2+) handling and substrate preference in cardiac muscle. Rats were treated with either 2 mg x kg(-1) x day(-1) Clen or saline (Sal) for 4 wk with the use of osmotic minipumps. Ventricular myocytes were enzymatically dissociated. Cells were field stimulated at 0.5, 1, and 2 Hz, and cytoplasmic Ca(2+) transients were monitored with the use of the fluorescent indicator indo-1 acetoxymethyl ester. Two-dimensional surface area and action potentials in current clamp were also measured. We found that in the Clen group there was significant hypertrophy at the organ and cellular levels compared with Sal. In Clen myocytes, the amplitude of the indo-1 ratio transients was significantly increased. Sarcoplasmic reticulum Ca(2+) content, estimated by rapid application of 20 mM caffeine, was significantly increased in the Clen group. The action potential was prolonged in the Clen group compared with Sal. Carbohydrate contribution to the tricarboxylic cycle (Krebs cycle) flux was increased several times in the Clen group. This increase was associated with decreased expression of peroxisome proliferator-activated receptor-alpha. This study shows that chronic administration of Clen induces cellular hypertrophy and increases oxidative carbohydrate utilization together with an increase in sarcoplasmic reticulum Ca(2+) content, which results in increased amplitude of the Ca(2+) transients. These effects could be important when Clen is used in conjunction with left ventricular assist devices treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15528231     DOI: 10.1152/ajpheart.00624.2004

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  20 in total

Review 1.  Reverse remodeling in heart failure--mechanisms and therapeutic opportunities.

Authors:  Norimichi Koitabashi; David A Kass
Journal:  Nat Rev Cardiol       Date:  2011-12-06       Impact factor: 32.419

Review 2.  State of the art of mechanical circulatory support.

Authors:  Hari R Mallidi; Jatin Anand; William E Cohn
Journal:  Tex Heart Inst J       Date:  2014-04-01

Review 3.  Pharmacology of manipulating lean body mass.

Authors:  Patricio V Sepulveda; Ernest D Bush; Keith Baar
Journal:  Clin Exp Pharmacol Physiol       Date:  2015-01       Impact factor: 2.557

4.  Effects of chronic treatment with the new ultra-long-acting β2 -adrenoceptor agonist indacaterol alone or in combination with the β1 -adrenoceptor blocker metoprolol on cardiac remodelling.

Authors:  Barbara Rinaldi; Maria Donniacuo; Loredana Sodano; Giulia Gritti; Eugenio Martuscelli; Augusto Orlandi; Concetta Rafaniello; Francesco Rossi; Luigino Calzetta; Annalisa Capuano; Maria Gabriella Matera
Journal:  Br J Pharmacol       Date:  2015-05-12       Impact factor: 8.739

5.  Atomoxetine prevents dexamethasone-induced skeletal muscle atrophy in mice.

Authors:  Sean R Jesinkey; Midhun C Korrapati; Kyle A Rasbach; Craig C Beeson; Rick G Schnellmann
Journal:  J Pharmacol Exp Ther       Date:  2014-10-07       Impact factor: 4.030

6.  Myocardial recovery with left ventricular assist devices.

Authors:  Maya Guglin; Leslie Miller
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-08

7.  A gene expression profile of the myocardial response to clenbuterol.

Authors:  Enrique Lara-Pezzi; Cesare M N Terracciano; Gopal K R Soppa; Ryszard T Smolenski; Leanne E Felkin; Magdi H Yacoub; Paul J R Barton
Journal:  J Cardiovasc Transl Res       Date:  2009-03-13       Impact factor: 4.132

8.  Chronic treatment with clenbuterol modulates endothelial progenitor cells and circulating factors in a murine model of cardiomyopathy.

Authors:  James E Rider; Sean P Polster; Sangjin Lee; Nathan J Charles; Neeta Adhikari; Ami Mariash; George Tadros; Jenna Stangland; Ryszard T Smolenski; Cesare M Terracciano; Paul J R Barton; Emma J Birks; Magdi H Yacoub; Leslie W Miller; Jennifer L Hall
Journal:  J Cardiovasc Transl Res       Date:  2009-03-27       Impact factor: 4.132

9.  Treatment strategies for myocardial recovery in heart failure.

Authors:  Andrew J Lenneman; Emma J Birks
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-03

10.  Effects of clenbuterol, a β₂-adrenergic agonist, on sizes of masseter, temporalis, digastric, and tongue muscles.

Authors:  Chieko Ishikawa; Takumi Ogawa; Tomoko Ikawa; Akira Yamane
Journal:  Open Dent J       Date:  2009-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.